Advanced search
Publication Cover
International Journal of General Medicine Volume 14, 2021 - Issue
Submit an article Journal homepage
100
Views
2
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients with Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study

Xiaoyu Liu1 Haematology Department of Shengjing Hospital, China Medical University, Shenyang, Liaoning, 110004, People’s Republic of ChinaView further author information
,
Hua Shi2 Haematology Department of Sun Yat-sen Memorial Hospital, Sun Yat-sen University Shen Shan Central Hospital, Guangzhou, People’s Republic of ChinaView further author information
,
Jing Shen1 Haematology Department of Shengjing Hospital, China Medical University, Shenyang, Liaoning, 110004, People’s Republic of ChinaView further author information
,
Yang Li1 Haematology Department of Shengjing Hospital, China Medical University, Shenyang, Liaoning, 110004, People’s Republic of ChinaView further author information
,
Wei Yan1 Haematology Department of Shengjing Hospital, China Medical University, Shenyang, Liaoning, 110004, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-6305-1011View further author information
ORCID Icon,
Ying Sun1 Haematology Department of Shengjing Hospital, China Medical University, Shenyang, Liaoning, 110004, People’s Republic of ChinaView further author information
,
Aijun Liao1 Haematology Department of Shengjing Hospital, China Medical University, Shenyang, Liaoning, 110004, People’s Republic of ChinaView further author information
,
Yehui Tan3 Haematology Department of The First Hospital of Jilin University, Changchun, Jilin, People’s Republic of ChinaView further author information
,
Wei Yang1 Haematology Department of Shengjing Hospital, China Medical University, Shenyang, Liaoning, 110004, People’s Republic of ChinaCorrespondence[email protected] [email protected]
View further author information
&
Huihan Wang1 Haematology Department of Shengjing Hospital, China Medical University, Shenyang, Liaoning, 110004, People’s Republic of ChinaView further author information
 show all
Pages 6093-6099 | Published online: 27 Sep 2021

References

  • Webster JA, Pratz KW. Acute myeloid leukemia in the elderly: therapeutic options and choice. Leuk Lymphoma. 2018;59(2):274–287. doi:10.1080/10428194.2017.1330956
  • Podoltsev NA, Stahl M, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Rev. 2017;31(2):43–62. doi:10.1016/j.blre.2016.09.005
  • Klepin HD, Rao AV, Pardee TS. Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol. 2014;32(24):2541–2552. doi:10.1200/JCO.2014.55.1564
  • Soura EN, Karikas GA. Acute myeloid leukaemia: recent data on prognostic gene mutations, in relation to stratified therapies for elderly patients. J BUON. 2019;24(4):1326–1339.
  • Klepin HD. Elderly acute myeloid leukemia: assessing risk. Curr Hematol Malig Rep. 2015;10(2):118–125. doi:10.1007/s11899-015-0257-2
  • Saito K, Nakamura Y, Aoyagi M, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol. 2000;71(3):238–244.
  • Liu J, Jia JS, Gong LZ, et al. Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC. Zhonghua Xue Ye Xue Za Zhi. 2018;39(9):734–738.
  • Ebbo M, Riviere E, Godeau B. Adult immune thrombocytopenia and thrombopoietin receptor agonist: ten years later. Rev Med Interne. 2020;S0248-8663:30208.
  • Chelvatheebam S, Langabeer SE, Linch DC, Hills RK, Greenwell P. Incidence and prognostic significance of C-MPL expression in acute myeloid leukemia. Leuk Res. 2003;27(9):869–870. doi:10.1016/S0145-2126(03)00016-X
  • Qian SX, Li JY, Tian T, et al. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. Leuk Res. 2007;31(10):1383–1388.
  • Kaushansky K. Thrombopoietin and its receptor in normal and neoplastic hematopoiesis. Thromb J. 2016;14(Suppl 1):40. doi:10.1186/s12959-016-0095-z
  • Ayala RM, Martinez-Lopez J, Albizua E, Diez A, Gilsanz F. Clinical significance of Gata-1, Gata-2, EKLF, and c-MPL expression in acute myeloid leukemia. Am J Hematol. 2009;84(2):79–86. doi:10.1002/ajh.21332
  • Archimbaud E, Ottmann OG, Yin JA, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood. 1999;94(11):3694–3701. doi:10.1182/blood.V94.11.3694
  • Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000;9(8):2530–2535. doi:10.1182/blood.V95.8.2530
  • Perl AE. Which novel agents will have a clinically meaningful impact in AML at diagnosis? Best Pract Res Clin Haematol. 2021;34(1):101257. doi:10.1016/j.beha.2021.101257
  • Li J, Chen Y, Zhu Y, et al. Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget. 2015;6(8):6448–6458. doi:10.18632/oncotarget.3361
  • Minakata D, Fujiwara S, Ito S, et al. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: a propensity score analysis. Leuk Res. 2016;42:82–87. doi:10.1016/j.leukres.2015.12.013
  • Suzushima H, Wada N, Yamasaki H, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia. Leuk Res. 2010;34(5):610–614. doi:10.1016/j.leukres.2009.08.010
  • Hirayama Y, Sakamaki S, Takayanagi N, et al. [Chemotherapy with ubenimex corresponding to patient age and organ disorder for 18 cases of acute myelogeneous leukemia in elderly patients–effects, complications and long-term survival]. Gan To Kagaku Ryoho. 2003;30(8):1113–1118. Japanese

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.